Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

B cell targeted therapy in autoimmunity.

Miri Blank1, Yehuda Shoenfeld

  • 1The Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.

Journal of Autoimmunity
|March 30, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exercise, autoimmune diseases and T-regulatory cells.

Journal of autoimmunity·2024
Same author

Helminth derivative tuftsin-phopshorylcholine to treat autoimmunity.

Autoimmunity reviews·2024
Same author

The contradictive findings between ultrasound, hysteroscopy and cytokines in women with nonhormonal IUDs suffering from menorrhagia: a prospective study.

Archives of gynecology and obstetrics·2024
Same author

Shared Pathogenicity Features and Sequences between EBV, SARS-CoV-2, and HLA Class I Molecule-binding Motifs with a Potential Role in Autoimmunity.

Clinical reviews in allergy & immunology·2023
Same author

Functional IgG Autoantibodies against Autonomic Nervous System Receptors in Symptomatic Women with Silicone Breast Implants.

Cells·2023
Same author

Anti-TPO-mediated specific features of the placenta immunohistochemical profile and possible mechanisms for fetal loss.

Clinical and experimental immunology·2023
Same journal

MuSK antibodies differently affect the MuSK signaling cascade depending on valency and epitope specificity.

Journal of autoimmunity·2026
Same journal

Neonatal total parenteral nutrition and the risk of childhood autoimmune diseases: A nationwide population-based study of 2.3 million children.

Journal of autoimmunity·2026
Same journal

Targeting autoreactive B cells in rheumatoid arthritis through MHC class I-presented BCR-derived neo-epitopes.

Journal of autoimmunity·2026
Same journal

Intermittent fasting ameliorates Sjögren's syndrome-related dry eye through a preponderant bile acid-Akkermansia homeostasis establishment.

Journal of autoimmunity·2026
Same journal

High-intensity immunosuppression versus modern standard care in poor-prognosis diffuse cutaneous systemic sclerosis: A propensity-matched study.

Journal of autoimmunity·2026
Same journal

Efficacy, safety, and tolerability of treatments for interstitial lung disease associated with rtoid arthritis: A systematic review and network meta-analysis.

Journal of autoimmunity·2026
See all related articles

Emerging therapies for autoimmune diseases target specific B cells, moving beyond broad immunosuppressants. These novel approaches, including co-stimulation blockers and B cell depletion, show promise in preclinical and clinical studies.

Area of Science:

  • Immunology
  • Autoimmune Diseases
  • Pharmacological Research

Background:

  • Autoimmunity arises from a loss of self-tolerance, leading to self-reactive B cells producing pathogenic autoantibodies.
  • These autoantibodies contribute to tissue damage via immune complex formation and complement activation.
  • Current treatments rely on broad immunosuppressants with significant long-term toxicities.

Purpose of the Study:

  • To review emerging therapeutic strategies for autoimmune diseases.
  • Focus on therapies targeting specific B cell populations or pathways.
  • Highlight novel approaches based on recent animal and human studies.

Main Methods:

  • Review of scientific literature on emerging autoimmune therapies.
  • Analysis of studies involving co-stimulation blockers.

Related Experiment Videos

  • Examination of compounds promoting B cell depletion.

    • Main Results:

    • Identification of co-stimulation blockers as a targeted therapy.
    • Evaluation of compounds causing specific B cell depletion.
    • Assessment of efficacy and safety from animal models and clinical trials.

    Conclusions:

    • Novel therapies offer a more targeted approach to autoimmune disease treatment.
    • Co-stimulation blockers and B cell depletion represent promising avenues.
    • Future treatments aim to improve efficacy while minimizing broad immunosuppressive toxicities.